Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
Park
John W
JW
University of California, San Francisco Cancer Center, San Francisco, California 94115-1710, USA. jpark@cc.ucsf.edu
Kerbel
Robert S
RS
Kelloff
Gary J
GJ
Barrett
J Carl
JC
Chabner
Bruce A
BA
Parkinson
David R
DR
Peck
Jonathan
J
Ruddon
Raymond W
RW
Sigman
Caroline C
CC
Slamon
Dennis J
DJ
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D014408:Biomarkers, Tumor; D002986:Clinical Trials as Topic; D015195:Drug Design; D004345:Drug Industry / Q000379:methods*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D012109:Research Support as Topic
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor